Mertk is known to activate multiple signaling pathways (MAPK, PI3K/AKT, JAK/STAT, and PD-1/PD-L1) in many types of cancer to promote immune tolerance, tumor progression and metastasis, and drug resistance (26, 60, 61). This evidence concerns the gene AKT1 and cancer.